Expert Interview
Discussing the approval and use of neoadjuvant/adjuvant durvalumab (Imfinzi) for resectable non-small cell lung cancer.
Ticker(s): AZN
Institution: University of Pennsylvania
- Medical oncologist/hematologist in practice for 19 years
- treats 22 patients with endometrial cancer per year
- familiar with the results from the DUO-E Phase III trial of Imfinzi (durvalumab) plus Lynparza (olaparib)
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
